文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

经导管主动脉瓣植入术后肾素-血管紧张素系统阻断治疗

Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation.
PubMed 文献 · Heart · 2017-10-06

该研究基于OCEAN-TAVI前瞻性注册研究,纳入1215例行TAVI的主动脉瓣狭窄患者,按术后是否使用ACEI/ARB分为RAS阻断组(n=371)与无RAS阻断组(n=189)。结果显示RAS阻断组6个月左室质量指数消退更显著,2年全因死亡率更低,校正混杂后RAS阻断与更低全因死亡相关。

要点

  • TAVI术后使用ACEI/ARB与6个月左室质量指数更显著消退相关(-9±24% vs -2±25%,p=0.024)。
  • RAS阻断组2年累积死亡率显著低于无RAS阻断组(7.5% vs 12.5%,p=0.031)。
  • 校正混杂因素后,RAS阻断与更低全因死亡独立相关(HR 0.45,95%CI 0.22-0.91,p=0.025)。

核心结论

  • TAVI术后RAS阻断治疗与更显著的左室质量指数消退及更低的全因死亡率相关。

研究设计与样本

  • 按术后是否使用ACEI或ARB分层:RAS阻断组(n=371)需至少两次处方间隔180天且随访至少6个月;无RAS阻断组(n=189)为术后未处方ACEI或ARB者。

主要发现

  • 术后6个月,RAS阻断组左室质量指数消退显著大于无RAS阻断组(-9±24% vs -2±25%,p=0.024)。
  • Kaplan-Meier分析显示RAS阻断组2年累积死亡率显著低于无RAS阻断组(7.5% vs 12.5%,log-rank p=0.031)。
  • 校正混杂因素后,RAS阻断治疗与更低的全因死亡率显著相关(HR 0.45;95%CI 0.22-0.91;p=0.025)。

临床怎么用

  • 对于TAVI术后患者,可考虑使用ACEI或ARB进行RAS阻断治疗,以促进左室肥厚消退并可能降低死亡风险。
  • 该观察性结果需前瞻性随机对照结局试验进一步确认后方可推荐为常规治疗。

局限性

  • 研究为观察性注册分析,非随机对照,存在选择偏倚和未测量混杂可能。
  • 作者指出结果需前瞻性随机对照结局试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The persistence of left ventricular (LV) hypertrophy is associated with poor clinical outcomes after transcatheter aortic valve implantation (TAVI) for aortic stenosis. However, the optimal medical therapy after TAVI remains unknown. We investigated the effect of renin-angiotensin system (RAS) blockade therapy on LV hypertrophy and mortality in patients undergoing TAVI. METHODS: Between October 2013 and April 2016, 1215 patients undergoing TAVI were prospectively enrolled in the Optimized CathEter vAlvular iNtervention (OCEAN)-TAVI registry. This cohort was stratified according to the postoperative usage of RAS blockade therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). Patients with at least two prescriptions dispensed 180 days apart after TAVI and at least a 6-month follow-up constituted the RAS blockade group (n=371), while those not prescribed any ACE inhibitors or ARBs after TAVI were included in the no RAS blockade group (n=189). RESULTS: At 6 months postoperatively, the RAS blockade group had significantly greater LV mass index regression than the no RAS blockade group (-9±24% vs -2±25%, p=0.024). Kaplan-Meier analysis revealed a significantly lower cumulative 2-year mortality in the RAS blockade than that in the no RAS blockade group (7.5% vs 12.5%; log-rank test, p=0.031). After adjusting for confounding factors, RAS blockade therapy was associated with significantly lower all-cause mortality (HR, 0.45; 95% CI 0.22 to 0.91; p=0.025). CONCLUSIONS: Postoperative RAS blockade therapy is associated with greater LV mass index regression and reduced all-cause mortality. These data need to be confirmed by a prospective randomised controlled outcome trial.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart. 2017. PMID: 28986405. doi:10.1136/heartjnl-2017-311738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。